Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Phase 2 Trial ◽

Open Label Phase ◽

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00163-7 ◽

2016 ◽

Vol 17 (6) ◽

pp. 791-800 ◽

Cited By ~ 259

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Ling-Ming Tseng ◽

Mei-Ching Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Randomised Trial ◽

Locally Advanced ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00373-3 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1700-1710 ◽

Cited By ~ 65

Author(s):

Javier Cortés ◽

Véronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Choice Of Treatment ◽

Abstract P4-14-08: Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial

10.1158/1538-7445.sabcs19-p4-14-08 ◽

2020 ◽

Author(s):

Yunjiang Liu ◽

Shuo Zhang

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Neoadjuvant Treatment ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70475-9 ◽

2014 ◽

Vol 15 (13) ◽

pp. 1493-1502 ◽

Cited By ~ 76

Author(s):

Bruno Coudert ◽

Jean-Yves Pierga ◽

Marie-Ange Mouret-Reynier ◽

Kaldoun Kerrou ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Fdg Pet ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

18F Fdg ◽

A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.11.004 ◽

2015 ◽

Vol 15 (2) ◽

pp. 101-109 ◽

Cited By ~ 27

Author(s):

Mothaffar F. Rimawi ◽

Sabina B. Aleixo ◽

Ashley Alarcon Rozas ◽

João Nunes de Matos Neto ◽

Maira Caleffi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

10.1158/1538-7445.sabcs17-ot1-03-03 ◽

2018 ◽

Author(s):

A Musolino ◽

S Gori ◽

L Cavanna ◽

C Graiff ◽

A Frassoldati ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Mechanism Of Action ◽

Locally Advanced ◽

Her2 Positive ◽

Open Label ◽

Immune Mediated ◽

Abstract PS13-12: Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial

10.1158/1538-7445.sabcs20-ps13-12 ◽

2021 ◽

Author(s):

Yunjiang Liu ◽

Xiangmei Zhang ◽

Li Wang ◽

Miao Cao ◽

Shuo Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Oncotarget ◽

10.18632/oncotarget.26286 ◽

2018 ◽

Vol 9 (86) ◽

pp. 35687-35704 ◽

Cited By ~ 18

Author(s):

Begoña Martin-Castillo ◽

Sonia Pernas ◽

Joan Dorca ◽

Isabel Álvarez ◽

Susana Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70049-9 ◽

2012 ◽

Vol 13 (4) ◽

pp. 375-384 ◽

Cited By ~ 107

Author(s):

Jean-Yves Pierga ◽

Thierry Petit ◽

Thierry Delozier ◽

Jean-Marc Ferrero ◽

Mario Campone ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

10.1158/1538-7445.am2012-2703 ◽

2012 ◽

Cited By ~ 2

Author(s):

Ruth M. O'Regan ◽

Sheryl Gabram ◽

Toncred Styblo ◽

Monica Rizzo ◽

William Wood ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Chemotherapy Regimen ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Trial ◽